Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2020

13.05.2020 | short review

Highlights of ASH 2019—multiple myeloma

verfasst von: Prof. Dr. Heinz Ludwig

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

The 2019 meeting of the American Society of Hematology (ASH) was dominated by new data from clinical research; effective combinations of mostly recently approved drugs and studies with new promising agents and treatment concepts, currently in the preapproval status, were on the forefront of attendee’s interest. Results from the ALCYONE study revealed a significant survival advantage with the addition of daratumumab, thus, highlighting the therapeutic potential of monoclonal antibodies. These antibodies are becoming standard combination partners for all lines of therapy. Presently, it remains unclear whether CAR‑T cells will win the race against immunoconjugates and other novel immunotherapies, or whether a combination of both will be used in the future, and not only at late relapse, but already as first-line therapy, particularly in high-risk disease. The large number of new drugs with new modes of activity will rescue an increasing number of patients with relapsed/refractory disease and, for sure, will move to earlier lines of therapy. ASH 2019 made it clear—the future is now.
Literatur
1.
Zurück zum Zitat Voorhees P, et al. Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): Griffin Study update. Blood. 2019;134:691. CrossRef Voorhees P, et al. Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): Griffin Study update. Blood. 2019;134:691. CrossRef
2.
Zurück zum Zitat Costa L, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-Krd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based Dara-Krd consolidation in patients with newly diagnosed multiple myeloma (NDMM). Blood. 2019;134:860. CrossRef Costa L, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-Krd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based Dara-Krd consolidation in patients with newly diagnosed multiple myeloma (NDMM). Blood. 2019;134:860. CrossRef
3.
Zurück zum Zitat Rifkin R, et al. Daratumumab (DARA) maintenance therapy improves depth of response and results in durable progression-free survival (PFS) following Dara plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): update of the Lyra Study. Blood. 2019;134:863. CrossRef Rifkin R, et al. Daratumumab (DARA) maintenance therapy improves depth of response and results in durable progression-free survival (PFS) following Dara plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): update of the Lyra Study. Blood. 2019;134:863. CrossRef
4.
Zurück zum Zitat Mateos M, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma: overall survival in alcyone. Blood. 2019;134:859. CrossRef Mateos M, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma: overall survival in alcyone. Blood. 2019;134:859. CrossRef
5.
Zurück zum Zitat Vij R, et al. Ixazomib or lenalidomide maintenance following autologous stem cell transplantation and ixazomib, lenalidomide, and dexamethasone (IRD) consolidation in patients with newly diagnosed multiple myeloma: results from a large multi-center randomized phase II trial. Blood. 2019;134:602. CrossRef Vij R, et al. Ixazomib or lenalidomide maintenance following autologous stem cell transplantation and ixazomib, lenalidomide, and dexamethasone (IRD) consolidation in patients with newly diagnosed multiple myeloma: results from a large multi-center randomized phase II trial. Blood. 2019;134:602. CrossRef
6.
Zurück zum Zitat Usmani S, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): primary analysis results from the randomized, open-label, phase 3 study Candor (NCT03158688). Blood. 2019;134:LBA‑6. CrossRef Usmani S, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): primary analysis results from the randomized, open-label, phase 3 study Candor (NCT03158688). Blood. 2019;134:LBA‑6. CrossRef
7.
Zurück zum Zitat Moreau P, et al. Evaluation of the prognostic value of positron emission tomography-computed tomography (PET-CT) at diagnosis and follow-up in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients treated in the phase 3 Cassiopeia study: results of the Cassiopet companion study. Blood. 2019;134:692. CrossRef Moreau P, et al. Evaluation of the prognostic value of positron emission tomography-computed tomography (PET-CT) at diagnosis and follow-up in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients treated in the phase 3 Cassiopeia study: results of the Cassiopet companion study. Blood. 2019;134:692. CrossRef
8.
Zurück zum Zitat Terpos E, et al. Progression-free survival analysis of denosumab vs zoledronic acid in intent to transplant multiple myeloma patients based on treatment regimen and baseline characteristics. Blood. 2019;134:606. CrossRef Terpos E, et al. Progression-free survival analysis of denosumab vs zoledronic acid in intent to transplant multiple myeloma patients based on treatment regimen and baseline characteristics. Blood. 2019;134:606. CrossRef
9.
Zurück zum Zitat Krishnan A, et al. Preliminary results from a phase 1b study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2019;134:140. CrossRef Krishnan A, et al. Preliminary results from a phase 1b study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2019;134:140. CrossRef
10.
Zurück zum Zitat Costa L, et al. First clinical study of the B‑cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134:143. CrossRef Costa L, et al. First clinical study of the B‑cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134:143. CrossRef
11.
Zurück zum Zitat Harrison S, et al. T(11;14) and high BCL2 expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: biomarker analyses from the phase 3 Bellini study. Blood. 2019;134:142. CrossRef Harrison S, et al. T(11;14) and high BCL2 expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: biomarker analyses from the phase 3 Bellini study. Blood. 2019;134:142. CrossRef
12.
Zurück zum Zitat Chen C, et al. Selinexor, pomalidomide, and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma. Blood. 2019;134:141. CrossRef Chen C, et al. Selinexor, pomalidomide, and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma. Blood. 2019;134:141. CrossRef
13.
Zurück zum Zitat Cowan A, et al. Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma. Blood. 2019;134:204. CrossRef Cowan A, et al. Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma. Blood. 2019;134:204. CrossRef
14.
Zurück zum Zitat Amatangelo M, et al. Multidimensional single cell analysis shows increased T/NK cell subsets in both blood and bone marrow of Iberdomide (CC-220) treated relapsed/refractory multiple myeloma patients. Blood. 2019;134:1775. CrossRef Amatangelo M, et al. Multidimensional single cell analysis shows increased T/NK cell subsets in both blood and bone marrow of Iberdomide (CC-220) treated relapsed/refractory multiple myeloma patients. Blood. 2019;134:1775. CrossRef
15.
Zurück zum Zitat Mateos M, et al. Clinical activity of Melflufen in patients with triple-class refractory multiple myeloma and poor-risk features in an updated analysis of HORIZON (OP-106), a phase 2 study in patients with relapsed/refractory multiple myeloma refractory to pomalidomide and/or daratumumab. Blood. 2019;134:1883. CrossRef Mateos M, et al. Clinical activity of Melflufen in patients with triple-class refractory multiple myeloma and poor-risk features in an updated analysis of HORIZON (OP-106), a phase 2 study in patients with relapsed/refractory multiple myeloma refractory to pomalidomide and/or daratumumab. Blood. 2019;134:1883. CrossRef
16.
Zurück zum Zitat Ocio E, et al. ANCHOR (OP-104): updated efficacy and safety from a phase 1/2 study of melflufen and dexamethasone plus bortezomib or daratumumab in patients with relapsed/refractory multiple myeloma (RRMM) refractory to an IMiD or a proteasome inhibitor (PI). Blood. 2019;134:3124. CrossRef Ocio E, et al. ANCHOR (OP-104): updated efficacy and safety from a phase 1/2 study of melflufen and dexamethasone plus bortezomib or daratumumab in patients with relapsed/refractory multiple myeloma (RRMM) refractory to an IMiD or a proteasome inhibitor (PI). Blood. 2019;134:3124. CrossRef
18.
Zurück zum Zitat Weisel K, et al. Dreamm-3: a phase 3, open-label, randomized study to evaluate the efficacy and safety of belantamab mafodotin (GSK2857916) monotherapy compared with pomalidomide plus low-dose dexamethasone (Pom/Dex) in participants with relapsed/refractory multiple myeloma (RRMM). Blood. 2019;134:1900. CrossRef Weisel K, et al. Dreamm-3: a phase 3, open-label, randomized study to evaluate the efficacy and safety of belantamab mafodotin (GSK2857916) monotherapy compared with pomalidomide plus low-dose dexamethasone (Pom/Dex) in participants with relapsed/refractory multiple myeloma (RRMM). Blood. 2019;134:1900. CrossRef
Metadaten
Titel
Highlights of ASH 2019—multiple myeloma
verfasst von
Prof. Dr. Heinz Ludwig
Publikationsdatum
13.05.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00612-1

Weitere Artikel der Ausgabe 3/2020

memo - Magazine of European Medical Oncology 3/2020 Zur Ausgabe